

Provet Veteriner Ürünleri San. ve Tic. A.Ş.

Balance Sheet as at 31 March 2023

All amounts are in Turkish Lira unless stated otherwise

Particulars	Note No.	As at 31 March 2023	As at 31 March 2022
<b>ASSETS</b>			
<b>1 Non-current assets</b>			
(a) Property, plant and equipment	3	5,51,56,884	1,84,62,965
(b) Capital work in progress	3	42,09,313	2,60,580
(c) Other Intangible assets	3	5,25,523	1,82,767
(d) Other non-current assets	4	37	-
(e) Financial assets			
(i) Investments	5	1,84,88,435	1,62,20,719
(f) Deferred tax assets (net)	6	34,46,261	43,44,053
		<b>8,18,26,454</b>	<b>3,94,71,083</b>
<b>2 Current assets</b>			
(a) Inventories	7	9,93,86,838	7,32,70,522
(b) Financial assets			
(i) Trade receivables	8	10,44,72,904	5,86,12,727
(ii) Cash and cash equivalents	9	11,05,547	25,27,926
(iii) Loans	10	71,736	56,19,813
(c) Other current assets	11	70,37,603	75,33,908
		<b>21,20,74,628</b>	<b>14,75,64,896</b>
<b>TOTAL ASSETS</b>		<b>29,39,01,082</b>	<b>18,70,35,979</b>
<b>EQUITY AND LIABILITIES</b>			
<b>1 Equity</b>			
(a) Equity share capital	12	30,10,244	20,00,000
(b) Other equity	12	6,54,75,792	2,03,21,077
		<b>6,84,86,036</b>	<b>2,23,21,077</b>
<b>2 Non-current liabilities</b>			
(a) Financial liabilities			
(i) Borrowings	13	-	1,82,160
(ii) Lease liability	30	8,43,185	9,40,378
(b) Long-term provisions	14	50,84,270	17,56,515
		<b>59,27,455</b>	<b>28,79,053</b>
<b>3 Current liabilities</b>			
(a) Financial liabilities			
(i) Short-term borrowings	15	11,89,33,199	9,32,18,364
(ii) Trade payables	16	6,97,65,422	6,21,99,929
(iii) Lease liability	30	99,165	83,155
(b) Other current liabilities	17	1,48,84,021	53,80,639
(c) Provisions	18	9,71,053	8,73,881
(d) Deferred tax liabilities (net)	19	1,48,34,730	-
(e) Current tax liabilities (net)	20	-	79,882
		<b>21,94,87,590</b>	<b>16,18,35,850</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>29,39,01,081</b>	<b>18,70,35,979</b>


See accompanying notes to the financial statements

2

As per our report of event date

EY Turkey

Auditors



Place : Istanbul

Date : 19th May 2022

For and on Behalf of the Board of Directors


Murat Mentec

Director

Thane, 19th May 2022

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çarşıbaşı Mahallesi, Kartal / İstanbul  
No: 28 / Kartal / İSTANBUL  
Kartal V.D.: 733 041 1925

Provet Veteriner Ürünleri San. ve Tic. A.Ş.  
Statement of Profit and Loss for the year ended 31 March 2023  
All amounts are in Turkish Lira unless stated otherwise

Particulars		Note No.	Year Ended 31 March 2023	Year Ended 31 March 2022
(I)	Revenue From Operations	21	31,37,63,781	13,19,82,537
(II)	Other Income	22	(89,17,181)	11,51,496
	<b>Total Income (I+ II)</b>		<b>30,48,46,600</b>	<b>13,31,34,032</b>
(III)	<b>EXPENSES</b>			
	Cost of materials consumed	23	17,51,18,331	7,34,55,153
	Changes in inventories of finished goods and work-in-progress & intermediates	24	(76,86,559)	(64,20,033)
	Employee benefits expense	25	4,60,48,612	2,35,14,872
	Finance costs	26	87,91,453	30,55,233
	Depreciation and amortization expense	27	60,24,612	42,20,059
	Other expenses	28	9,06,07,764	6,30,26,457
	<b>Total expenses (III)</b>		<b>31,89,04,212</b>	<b>16,08,51,742</b>
(IV)	<b>Profit before tax</b>		<b>(1,40,57,612)</b>	<b>(2,77,17,710)</b>
(V)	Tax expense:	29		
	(1) Current tax		-	-
	(2) Previous tax		-	(60,89,302)
	(2) Deferred tax		49,21,073	(45,38,212)
	<b>Total Tax (V)</b>		<b>49,21,073</b>	<b>(1,06,27,514)</b>
(VI)	<b>Profit (Loss) for the period (IV-V)</b>		<b>(1,89,78,684)</b>	<b>(1,70,90,196)</b>
(VII)	Other Comprehensive Income		(41,58,997)	(7,08,874)
(VIII)	<b>Total Comprehensive Income for the period (VI+VII)</b>		<b>(2,31,37,681)</b>	<b>(1,77,99,070)</b>
(IX)	Earnings per equity share:	31		
	(1) Basic		(1,15,688)	(88,995)
	(2) Diluted		(1,15,688)	(88,995)
	<b>See accompanying notes to the financial statements</b>	2		
As per our report of event date		For and on Behalf of the Board of Directors		
EY Turkey Auditors		Murat Mentes Director		
Place : Istanbul		Thane, 19th May 2022		
Date : 19th May 2022		 <b>PROVET VETERİNER ÜRÜNLERİ SAN. VE TİC. A.Ş.</b> Kuruluş Yılı: 1997 / Kuruluş Yeri: İstanbul / Türkiye No: 28 Kartal / İSTANBUL Kartal V.D. 733 041 1026		

Provet Veteriner Ürünleri San. ve Tic. A.Ş.  
Statement of cash flows for the year ended 31 March, 2023  
All amounts are in Turkish Lira unless stated otherwise

Particulars	Year ended 31 March, 2023	Year ended 31 March, 2022
<b>Cash flow from Operating Activities :-</b>		
Net Profit before tax	(1,40,57,612)	(2,77,17,710)
Adjustments for:		
Finance costs	87,91,453	30,55,233
Depreciation and amortisation expenses	60,24,612	42,20,059
ESOP Expenses	9,07,086	11,08,287
Interest Income	(11,08,409)	(16,816)
Profit/Loss on sale of property, plant and equipment (net)	(43,98,225)	74,943
Profit on sale of investment (net)	(21,745)	(1,19,129)
Unrealised forex loss on loan (net)	2,50,33,651	3,51,81,265
Opening Inventory Adjustment Ind AS 29	2,06,73,461	-
Monetary Gain PL Ind AS 29	1,59,31,739	-
Allowance for doubtful trade receivables	-	-
<b>Operating profit before working capital changes</b>	<b>5,77,76,010</b>	<b>1,57,86,132</b>
<b>Change in working Capital</b>		
(Increase) / decrease in trade receivables, loans and advances and other assets	(3,98,15,795)	(76,10,898)
(Increase) / decrease in inventories	(2,61,16,315)	(4,40,20,163)
Increase / (decrease) in trade payables, other payables and provisions	1,65,61,776	3,55,45,196
<b>Net change in working capital</b>	<b>(4,93,70,335)</b>	<b>(1,60,85,865)</b>
<b>Cash generated from operations</b>	<b>84,05,675</b>	<b>(2,99,732)</b>
Direct taxes (paid)/refund	(79,882)	(3,53,641)
<b>Net cash generated from operating activities</b>	<b>83,25,794</b>	<b>(6,53,374)</b>
<b>Cash Flow from Investing activities</b>		
Purchase of property, plant and equipment and intangible assets	(82,44,034)	(36,26,735)
Proceeds from disposal of property, plant and equipment and intangible assets	44,54,015	1,91,482
(Purchase) / sale of current investments (net)	21,745	1,19,129
Interest received	11,08,409	16,816
<b>Net cash used in investing activities</b>	<b>(26,59,864)</b>	<b>(32,99,308)</b>
<b>Cash flow from Financing activities</b>		
Repayment of loan	(2,76,60,116)	(25,41,318)
Proceed from loan	2,40,00,000	85,00,000
Interest paid	(34,28,192)	(9,48,458)
<b>Net cash used in investing activities</b>	<b>(70,88,308)</b>	<b>50,10,224</b>
<b>Net (decrease) in cash and cash equivalents during the year</b>	<b>(14,22,379)</b>	<b>10,57,543</b>
<b>Opening Cash &amp; cash equivalent at the beginning of the year</b>	<b>25,27,926</b>	<b>14,70,383</b>
<b>Cash and cash equivalents at the end of the year</b>	<b>11,05,547</b>	<b>25,27,926</b>
<b>Reconciliation of cash and cash equivalents with the Balance sheet</b>		
Cash on hand	3,035	6,105
Balances with banks	11,02,512	25,21,821
<b>Cash and cash equivalents as per Balance Sheet (Refer Note 8)</b>	<b>11,05,547</b>	<b>25,27,926</b>
The accompanying notes are an integral part of the financial statements.	0	(0)

As per our report of event date  
EY Turkey  
Auditors

Place : Istanbul  
Date : 19th May 2022

For and on Behalf of the Board of Directors

Murat Mentec  
Director  
Thane, 19th May 2022

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Kuruluşu: 06.05.1987  
No: 11000000000000000000  
Kartal IV. Cad. 733 041 1925

Provet Veteriner Ürünleri San. ve Tic. A.Ş.  
Statement of Changes in Equity (SOCIE) for the period ended 31 March, 2023  
All amounts are in Turkish Lira unless stated otherwise

(a) Equity share capital

Particulars	As at 31 March, 2023		As at 31 March, 2022	
	No. of Shares	Amount	No. of Shares	Amount
Balance at the beginning of the reporting period	200	20,00,000	200	20,00,000
Changes in equity share capital during the year/ period	-	-	-	-
Share Capital Impact Ind AS29	-	10,10,244	-	-
Balance at the end of the reporting period	200	30,10,244	200	20,00,000

(b) Other Equity

Reserves and Surplus	Year ended 31st March 2023						Year ended 31st March 2022					
	General reserve	Revaluation reserve	Capital reserve	OCI	Retained Earnings	Total	General reserve	Revaluation reserve	Capital reserve	OCI	Retained Earnings	Total
Opening balance	1,22,53,825	51,82,487	49,339	(9,17,042)	37,52,469	2,03,21,077	1,22,53,825	51,82,487	49,339	(2,08,168)	1,69,63,658	3,42,41,140
Profit for the period	-	-	-	(41,58,997)	(1,22,40,849)	(1,63,99,846)	-	-	-	(7,08,874)	(1,32,11,190)	(1,39,20,064)
Hyperinflation Impact	61,89,675	26,17,787	24,922	-	5,27,22,178	6,15,54,562	-	-	-	-	-	-
Closing balance	1,84,43,499	78,00,274	74,261	(50,76,039)	4,42,33,798	6,54,75,792	1,22,53,825	51,82,487	49,339	(9,17,042)	37,52,469	2,03,21,077

The accompanying notes are an integral part of the financial statements.

As per our report of event date  
EY Turkey  
Auditors

Place : Istanbul  
Date : 19th May 2022

For and on Behalf of the Board of Directors

Murat Mentis  
Director  
Thane, 19th May 2022

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çavuşoğlu Mah. Başkumandan Cad.  
No: 28 / Kartal / İSTANBUL  
Kartal / İstanbul : 733 041 1936

SADECE BELİRLENEN AMAÇLI İMZALANMIŞTIR  
GÖNEY BAĞIMSIZ DENETİM VE SMMM A.Ş.

## 1. CORPORATE INFORMATION

Provet Veteriner Ürünleri San. ve Tic. A.Ş. ('the Company') is a company duly organised and incorporated in accordance with the laws of Turkey and is engaged in the manufacturing and marketing of pharmaceuticals products.

### 2.1 Statement of compliance

The financial statements have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 and as amended from time to time and presentation requirements of Division II of Schedule III to the Companies Act, 2013.

### 2.2 Basis of preparation and presentation

The financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values at the end of each reporting period.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. Fair value for measurement and / or disclosure purposes in these financial statements is determined on such a basis, except for

- Leasing transaction as defined in Ind AS 116 – Leases.
- Measurement that have some similarities to fair value but are not fair value, such as 'Net Realisable Value' as defined in Ind AS 2 – Inventories and value in use as defined in Ind AS 36- Impairment of Assets.

The financial statements have been prepared on accrual and going concern basis. The accounting policies are applied consistently to all the periods presented in the financial statements. All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle. Based on the nature of services and the time between acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current or non-current classification of assets and liabilities.

### 2.3 Functional and presentation currency

These financial statements are presented in Turkish Lira (TL), which is the Company's functional currency.

### 2.4 Significant Accounting Policies

#### i. Revenue Recognition

##### Sale of products

Revenue from sale of products is presented in the income statement within revenue from operations. The Company presents revenue net of indirect taxes in its statement of profit and loss. Sale of products comprise revenue from sales of products, net of sales returns, Turnover premium and customer discounts.

Revenue is recognized when it is probable that future economic benefits will flow to the Company and these benefits can be measured reliably. Further, revenue recognition requires that all significant risks and rewards of ownership of the goods included in the transaction have been transferred to the buyer, and that Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold. Performance obligations are satisfied at one point in time, typically on delivery. Revenue is recognized when the Company transfers control over the product to the customers; control of a product refers to the ability to direct the use of, and obtain substantially all of the remaining benefits from, that asset. The majority of revenue earned by the Company is derived from the satisfaction of a single performance obligation for each contract which is the sale of products.

Sales are measured at the fair value of consideration received or receivable. The amounts of turnover premium is estimated and accrued on each of the underlying sales transactions recognised.

##### Interest income

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable.

#### ii. Leases

Ind AS 116 supersedes Ind AS 17 Leases. The standard sets out the principles for the recognition, measurement, presentation and disclosure of leases and requires lessees to recognise most leases on the balance sheet.

The Company adopted Ind AS 116 using the modified retrospective method of adoption with the date of initial application of 01 April 2019. Under this method, the standard is applied retrospectively with the cumulative effect of initially applying the standard recognised at the date of initial application.

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çavuşbaşı Mah. Beşiktaş/İstanbul  
Kartal V.C. 733 041 1925

**Leases previously accounted for as operating leases**

The Company recognised right-of-use assets and lease liabilities for those leases previously classified as operating leases, except for short-term leases and leases of low-value assets. The right-of-use assets for most leases were recognised based on the carrying amount as if the standard had always been applied, apart from the use of incremental borrowing rate at the date of initial application. In some leases, the right-of-use assets were recognised based on the amount equal to the lease liabilities, adjusted for any related prepaid and accrued lease payments previously recognised. Lease liabilities were recognised based on the present value of the remaining lease payments, discounted using the incremental borrowing rate at the date of initial application. The Right of Use asset are depreciated on a straight - line basis over the lease term.

The Company also applied the available practical expedients wherein it:

- Used a single discount rate to a portfolio of leases with reasonably similar characteristics,
- Relied on its assessment of whether leases are onerous immediately before the date of initial application,
- Applied the short-term leases exemptions to leases with lease term that ends within 12 months of the date of initial application,
- Excluded the initial direct costs from the measurement of the right-of-use asset at the date of initial application,
- Used hindsight in determining the lease term where the contract contained options to extend or terminate the lease.

**iii. Foreign currency transactions and translation**

Transactions in currencies other than the entity's functional currency (foreign currencies) are recognised at the rates of exchange prevailing at the dates of the transactions.

At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Exchange differences arising on settlement or translation of monetary items are recognised in the statement of profit and loss in the year in which it arises.

Non-monetary assets and liabilities denominated in foreign currencies that are measured at fair value are retranslated to the functional currency at the exchange rate at the date when the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.

Exchange difference on capital expenditure are not capitalised but charged to the statement of profit and loss.

**iv. Borrowing costs**

Borrowing costs directly attributable to the acquisition, construction or erection of qualifying assets are added to the cost of those assets, until such time that the assets are substantially ready for their intended use. Qualifying assets are assets which take a substantial period of time to get ready for their intended use or sale.

Interest income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalisation.

All other borrowing costs are recognised in the statement of profit and loss in the period in which they are incurred.

**v. Employee Benefits**

**a) Defined contribution plans**

The Company has defined contribution plans for post-employment benefits in the form of Social security which is administered through Government of Turkey. Social Security is classified as defined contribution plans as the Company has no further obligation beyond making the contributions. The company's contributions to defined contribution plans are charged to the statement of profit and loss as and when employee renders related service.

**b) Defined benefit plans**

Payments to defined benefit plans are recognised as an expense when employees have rendered service entitling them to the contributions.

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The Company's Severance pay is in the nature of defined benefit plans.

For defined benefit plans, the cost of providing benefit is determined using projected unit credit method, with actuarial valuation being carried out at the end of each financial year. Re-measurement, comprising actuarial gains and losses, the effect of the changes to the asset ceiling (if applicable) and the return on plan assets (excluding net interest), is reflected immediately in the balance sheet with a charge or credit recognised in other comprehensive income in the period in which they occur. Re-measurement recognised in other comprehensive income is reflected immediately in retained earnings and is not reclassified to the statement of profit and loss. Past service cost is recognised in the statement of profit and loss in the period of a plan amendment. Net interest is calculated by applying the discount rate at the beginning of the period to the net defined benefit liability or asset. Defined benefit costs are categorised as follows:

- service cost (including current service cost, past service cost, as well as gains and losses on curtailments and settlements);
- net interest expense or income; and
- re-measurement gain / (loss).

The Company presents the service cost of defined benefit plan in the line item 'Employee benefits expense' and the net interest expense or income in the line item 'Finance costs' of the statement of profit and loss. The retirement benefit obligation recognised in the balance sheet represents the actual deficit or surplus in the Company's defined benefit plans. Any surplus resulting from this calculation is limited to the present value of any economic benefits available in the form of refunds from the plans or reductions in future contributions to the plans.

c) **Short-term employee benefits**

A liability is recognised for short-term employee benefit in respect of wages and salaries, annual leaves, medical and leave travel in the period the related service is rendered at the undiscounted amount of the benefits expected to be paid in exchange for that service.

d) **Other employee benefits**

Other employee benefits comprise of leave encashment which is provided for, based on the actuarial valuation carried out as at the end of the year. Liabilities recognised in respect of other employee benefits are measured at the present value of the estimated future cash outflows expected to be made by the Company in respect of services provided by employees up to the reporting date.

vi **Taxes on income**

Income tax comprises current and deferred tax. Income tax expense is recognised in the statement of profit and loss except to the extent it relates to items directly recognised in equity or in other comprehensive income.

vii. **Property, plant and equipment**

a) **Recognition and measurement**

Property, Plant and Equipment are stated at cost, net of recoverable taxes, trade discount and rebates less accumulated depreciation and impairment losses, if any.

Cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for its intended use. The cost of self-constructed assets includes the cost of materials and other costs directly attributable to bringing the asset to a working condition for its intended use.

When parts of an item of property, plant and equipment have significant cost in relation to total cost and different useful lives, they are recognised and depreciated separately.

Depreciation is recognised so as to write off the cost of assets (other than freehold land) less their residual values, using the straight-line method, over the useful lives

Nature of the assets	Useful life in years
Freehold land	-
Factory building	21 years
Furniture and fixtures	5 years
Office equipments	5 years
Computers	4 years
Plant and machinery	10 years
Vehicles	8 years

The estimated useful lives, residual values and depreciation method are reviewed at financial year end, with the effect of any changes in estimates are accounted for on a prospective basis.

b) **Subsequent costs**

The cost of replacing part of an item of property, plant and equipment is recognised in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The costs of repairs and maintenance are recognised in the statement of profit and loss as incurred.

c) **Derecognition of property, plant and equipment**

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised in the statement of profit and loss.

viii. **Intangible assets**

a) **Intangible assets acquired separately**

Intangible assets that are acquired by the Company, which have finite useful lives, are measured at cost less accumulated amortisation and accumulated impairment losses. Amortisation is recognised on straight-line basis over the estimated useful lives. The estimated useful life and amortisation method are reviewed at the end of each financial year, with the effect of any changes in estimate being accounted for on a prospective basis. Cost includes any directly attributable incidental expenses necessary to make the assets ready for use.

**Useful lives of intangible assets**

Estimated useful lives of the intangible assets are as follow:

Nature of the assets	Useful life in years
Software	3-5

b) **Subsequent costs**

Subsequent costs are capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditures, including expenditure on internally-generated intangibles, are recognised in the statement of profit and loss as incurred.

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çengelköy Mahallesi, Çengelköy Cad.  
No: 28, Kat: 7 / İSTANBUL  
Kartal V.B.: 789 041 1825

**c) Derecognition of intangible assets**

An intangible asset is derecognised on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset are recognised in the statement of profit and loss.

**ix. Inventories**

Inventories comprises of consumables used for analytical purposes. These are valued at the lower of cost and net realizable value. Cost is determined on First in First out basis, at purchase cost including other cost incurred in bringing consumables to their present location and condition.

**x. Provisions and contingent liabilities**

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of each reporting period, taking into account the risks and uncertainties surrounding the obligation.

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognised as an asset, if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount cannot be made. Contingent liabilities are not recognised but are disclosed in the notes to financial statements. Contingent assets are not recognised but are disclosed in the notes to financial statements when economic inflow is probable.

**xi. Financial instruments**

Financial assets and financial liabilities are recognised when an entity becomes a party to the contractual provisions of the instruments.

All financial instruments are initially measured at fair value. Transaction costs that are attributable to the acquisition or issue of the financial assets and financial liabilities (other than financial assets recorded at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities as appropriate, on initial recognition. Transaction cost directly attributable to the acquisition or issue of financial assets or financial liabilities at fair value through profit or loss are recognised immediately in the statement of profit and loss.

Purchase or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trade) are recognised on trade date.

For the purpose of subsequent measurement, financial instruments of the Company are classified in the following categories: non-derivative financial assets comprising amortised cost, debt instruments at fair value through other comprehensive income (FVTOCI), equity instruments at fair value through other comprehensive income (FVTOCI) and fair value through profit or loss (FVTPL), non-derivative financial liabilities at amortised cost or FVTPL and derivative financial instruments (under the category of financial assets or financial liabilities) at FVTPL.

The classification of financial instruments depends on the objective of the business model for which it is held. Management determines the classification of its financial instruments at initial recognition.

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çavuşlu, Çavuşlu Mahallesi, Çavuşlu Cad.  
No: 20 Kat: 7 İSTANBUL  
Kartal/V.E.: 799 041 1088



**xii Impairment**

**a) Financial assets**

In accordance with Ind AS 109 - Financial Instruments, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss. The Company follows 'simplified approach' for recognition of impairment loss allowance on trade receivable.

The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting period, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. Lifetime ECLs are the expected credit losses resulting from all possible default events over the expected life of a financial instrument.

ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive (i.e. all shortfalls), discounted at the original EIR. When estimating the cash flows, an entity is required to consider:

(i) All contractual terms of the financial instrument (including prepayment, extension etc.) over the expected life of the financial instrument. However, in rare cases when the expected life of the financial instrument cannot be estimated reliably, then the entity is required to use the remaining contractual term of the financial instrument;

(ii) Cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

As a practical expedient, the Company uses a provision matrix to determine impairment loss on portfolio of its trade receivable. The provision matrix is based on its historically observed default rates over the expected life of the trade receivable and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in forward-looking estimates are analysed.

ECL impairment loss allowance (or reversal) recognised during the period is recognised as income / expense in the statement of profit and loss. This amount is reflected under the head other expenses in the statement of profit and loss. The balance sheet presentation for various financial instruments is described below:

Financial assets measured at amortised cost, contractual revenue receivables. ECL is presented as an allowance, i.e. as an integral part of the measurement of those assets in the balance sheet. The allowance reduces the net carrying amount. Until the asset meets write off criteria, the Company does not reduce impairment allowance from the gross carrying amount.

**b) Non-financial assets**

The Company assesses at each reporting date whether there is any objective evidence that a non-financial asset or a group of non-financial assets is impaired. If any such impairment exists, the recoverable amount of an asset is estimated to determine extent of impairment, if any. Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

**xiii Earnings per share**

Basic EPS is computed by dividing the net profit for the period attributable to the equity shareholders by the weighted average number of equity shares outstanding during the period.

Diluted EPS is computed by dividing the net profit after tax by the weighted average number of equity shares considered for deriving basic EPS and also weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the period, unless issued at a later date. Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for bonus shares, as appropriate.

**xiv Cash and cash equivalents**

Cash and cash equivalents in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

**xv Segment**

Segments have been identified taking into account the nature of services, the differing risks and returns, the organisational structure and the internal reporting system.

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çavuşlu, Kızılkaya Mahallesi, Kuruhanlı Cad.  
No: 28 Kat: 7 / İSTANBUL  
Kartal/V.C.: 733 041 1925

**xvi Current versus non-current classification**

The Company presents assets and liabilities in the balance sheet based on current / non-current classification.

An asset is treated as current when:

- It is expected to be realised or intended to be sold or consumed in normal operating cycle,
- It is held primarily for the purpose of trading,
- It is expected to be realised within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

All other liabilities are classified as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

**xvii Fair value measurement**

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability or
- In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities.
- Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.
- Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

**2A. Use of estimates and management judgments**

In application of the accounting policies, which are described in note 2, the management of the Company is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised if the revision affects only that period, or in the period of revision and future periods if the revision affects both current and future periods. In particular, information about significant areas of estimation, uncertainty and critical judgements used in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements is included in the following notes:

**i Deferred tax**

Deferred income tax liabilities are recognised for all taxable temporary differences. Deferred income tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilised.

**ii. Fair value**

Management uses valuation techniques in measuring the fair value of financial instruments where active market quotes are not available. In applying the valuation techniques, management makes maximum use of market inputs and uses estimates and assumptions that are, as far as possible, consistent with observable data that market participants would use in pricing the instrument. Where applicable data is not observable, management uses its best estimate about the assumptions that market participants would make. These estimates may vary from the actual prices that would be achieved in an arm's length transaction at the reporting date.

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çayırdan Mh. Başkumandan Cad.  
No: 28 Karşı / İSTANBUL  
Kart. IV. Da: 703 041 1020

iii. **Post-retirement benefit plans**

The obligation arising from the defined benefit plan is determined on the basis of actuarial assumptions which include discount rate, trends in salary escalation and vested future benefits and life expectancy. The discount rate is determined with reference to market yields at each financial year end on the government bonds.

iv. **Provisions and contingencies**

The recognition and measurement of other provisions are based on the assessment of the probability of an outflow of resources, and on past experience and circumstances known at the reporting date. The actual outflow of resources at a future date may therefore vary from the figure estimated at end of each reporting period.

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
ÇAYIROĞLU MAH. İSTANBUL CAD.  
KAT: 11 / İSTANBUL  
KURUM NO: 733 041 1925

Note 3: Property, Plant and equipment, Capital work in progress & Other Intangible assets  
All amounts are in Turkish Lira unless stated otherwise

Particulars	As at	As at
	31 March, 2023	31 March, 2022
<b>Carrying Amount of:</b>		
Freehold land	25,32,754	7,98,480
Factory Building	2,61,12,199	81,46,955
Furniture and fixtures	2,17,971	86,577
Office equipments	6,78,205	2,04,633
Computers	1,18,577	62,492
Plant and machinery	1,94,94,320	60,99,974
ROU Lease Asset	18,00,991	6,69,579
Vehicles	42,01,867	23,94,275
	<b>5,51,56,884</b>	<b>1,84,62,965</b>
Capital work-in-progress	42,09,313	2,60,580
Acquired software	5,25,523	1,82,767
<b>Total</b>	<b>5,98,91,720</b>	<b>1,89,06,312</b>

Cost or deemed cost	Tangible asset								Intangible asset	Total
	Free hold land	Factory Building	Furniture and fixtures	Office equip.	Computer	Plant and machinery	ROU Lease Asset	Vehicles	Acquired software	
Balance as on 01 April, 2021	7,98,480	1,02,58,592	5,15,957	4,24,097	3,36,886	1,24,58,345	10,08,092	67,21,306	6,53,336	3,31,75,093
Transition impact of Ind AS 116	-	-	-	-	-	-	-	-	-	-
Assets acquired during the year	-	6,190	48,850	1,41,254	21,825	27,40,810	-	5,48,670	2,00,848	37,08,448
Modifications during the year	-	-	-	-	-	-	-	-	-	-
Deletions	-	-	-	-	-	-	-	3,13,441	-	3,13,441
Disposed under slump sale (Refer Note xx)	-	-	-	-	-	-	-	-	-	-
<b>Balance as on 31 March, 2022</b>	<b>7,98,480</b>	<b>1,02,64,782</b>	<b>5,64,807</b>	<b>5,65,351</b>	<b>3,58,711</b>	<b>1,51,99,155</b>	<b>10,08,092</b>	<b>69,56,535</b>	<b>8,54,185</b>	<b>3,65,70,099</b>
Balance as on 01 April, 2022	7,98,480	1,02,64,782	5,64,807	5,65,351	3,58,711	1,51,99,155	10,08,092	69,56,535	8,54,185	3,65,70,099
Assets acquired during the year	-	4,56,724	6,400	1,28,935	10,169	30,30,138	-	53,610	1,21,774	38,07,751
Modifications during the year*	17,34,274	1,78,80,026	1,49,253	4,64,393	81,194	1,33,48,510	12,33,208	28,77,180	3,59,846	3,81,27,883
Deletions/Discontinuation of ROU Asset	-	-	-	-	-	-	-	12,45,679	-	12,45,679
<b>Balance as on 31 March, 2023</b>	<b>7,98,480</b>	<b>1,07,21,507</b>	<b>5,71,207</b>	<b>6,94,287</b>	<b>3,68,881</b>	<b>1,82,29,294</b>	<b>22,41,300</b>	<b>86,41,646</b>	<b>9,75,958</b>	<b>7,72,60,054</b>

Accumulated Depreciation	Tangible asset								Intangible asset	Total
	Free hold land	Factory Building	Furniture and fixtures	Office equip.	Computer	Plant and machinery	ROU Lease Asset	Vehicles	Acquired software	
Balance as on 01 April, 2021	-	16,29,566	4,52,501	2,51,846	2,48,137	71,90,376	2,36,717	32,91,535	4,50,647	1,37,51,325
Depreciation / amortisation expense for the year	-	4,88,262	25,729	1,08,872	48,082	19,08,805	1,01,797	13,17,741	2,20,770	42,20,059
Deletions during the year	-	-	-	-	-	-	-	47,016	-	47,016
<b>Balance as on 31 March, 2022</b>	<b>-</b>	<b>21,17,828</b>	<b>4,78,230</b>	<b>3,60,719</b>	<b>2,96,219</b>	<b>90,99,181</b>	<b>3,38,514</b>	<b>45,62,260</b>	<b>6,71,417</b>	<b>1,79,24,368</b>
Balance as on 01 April, 2022	-	21,17,828	4,78,230	3,60,719	2,96,219	90,99,181	3,38,514	45,62,260	6,71,417	1,79,24,368
Depreciation / amortisation expense for the year	-	3,71,506	24,259	1,19,756	35,279	29,84,302	1,01,795	10,67,408	1,38,864	48,43,169
Deletions during the year	-	-	-	-	-	-	-	11,89,889	-	11,89,889
<b>Balance as on 31 March, 2023</b>	<b>-</b>	<b>24,89,333</b>	<b>5,02,489</b>	<b>4,80,475</b>	<b>3,31,498</b>	<b>1,20,83,483</b>	<b>4,40,309</b>	<b>44,39,779</b>	<b>8,10,281</b>	<b>2,15,77,647</b>

Carrying amount	Tangible asset								Intangible asset	Total
	Free hold land	Factory Building	Furniture and fixtures	Office equip.	Computer	Plant and machinery	ROU Lease Asset	Vehicles	Acquired software	
Balance as on 31 March, 2022	7,98,480	81,46,955	86,577	2,04,633	62,492	60,99,974	6,69,579	23,94,275	1,82,767	1,86,45,732
<b>Balance as on 31 March, 2023</b>	<b>25,32,754</b>	<b>2,61,12,199</b>	<b>2,17,971</b>	<b>6,78,205</b>	<b>1,18,577</b>	<b>1,94,94,320</b>	<b>18,00,991</b>	<b>42,01,867</b>	<b>5,25,523</b>	<b>5,56,82,407</b>

\*Hyper Inflation Impact INDAS29

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çarşıbaşı Mahallesi, Çarşıbaşı Sokakı  
No: 28 Kat: 1 / İSTANBUL  
Kartal V.C.: 733 041 1925

SADECE BELİRLEME AMACI İMZALANMIŞTIR  
GÖNEY BAĞIMSIZ DENETİM VE SMİM A.Ş.

Notes	Particulars	As at 31 March 2023	As at 31 March 2022
4	<b>Other non-current assets</b>		
	Advance Income-Tax including tax deducted at source	37	-
5	<b>Non-current Investments</b>		
	Investments in equity instruments of 100% Subsidiary (Nos of Shares held in Topkim - 100,000,000 at face value of TL 0.01/Share)	1,84,88,435	1,62,20,719
		<b>1,84,88,435</b>	<b>1,62,20,719</b>
6	<b>Deferred tax assets (net)</b>		
	On account of Losses	25,85,770	37,93,549
	On account of Lease	93,642	88,489
	On account of ESOP	5,03,843	2,77,072
	Others	2,63,006	1,84,943
		<b>34,46,261</b>	<b>43,44,053</b>
7	<b>Inventories</b> (At lower of cost and net realisable value)		
	Raw materials and packing materials	7,30,99,810	5,91,84,721
	Goods-in transit	25,75,023	
		7,56,74,833	5,91,84,721
	Work-in-progress and intermediates	26,24,636	15,21,558
	Finished goods	2,10,87,368	1,25,64,243
		<b>9,93,86,838</b>	<b>7,32,70,522</b>
	During the year ended 31 March 2023 TRY 1,178,818 (31 March 2022 TRY 1,748,811) was recognised as an expense towards provision for slow moving, expired and near expiry inventories		
8	<b>Trade receivables</b>		
	Unsecured, considered good	10,44,72,904	5,86,12,727
	Unsecured, considered doubtful	12,63,940	12,63,940
		10,57,36,844	5,98,76,667
	Less: Allowances for doubtful debts	(12,63,940)	(12,63,940)
		<b>10,44,72,904</b>	<b>5,86,12,727</b>
<b>March'23</b>			
	Particulars	Not Due	Outstanding for following periods fromdue date of payment #
			Less than 6 months
			6 months - 1 years
			1-2 years
			2-3 years
			More than 3 years
			Total
	(i) Undisputed Trade Receivables - considered good	9,13,81,784	1,14,03,298
			10,17,567
			5,36,938
			1,33,318
			-
			10,44,72,904
	(ii) Undisputed Trade Receivables - considered doubtful	-	-
		-	-
		-	-
		-	-
		-	12,63,940
		-	12,63,940
	Grand Total	9,13,81,784	1,14,03,298
			10,17,567
			5,36,938
			1,33,318
			12,63,940
			10,57,36,844
<b>March'22</b>			
	Particulars	Not Due	Outstanding for following periods fromdue date of payment #
			Less than 6 months
			6 months - 1 years
			1-2 years
			2-3 years
			More than 3 years
			Total
	(i) Undisputed Trade Receivables - considered good	5,20,55,313	62,35,590
			1,84,535
			1,33,318
			3,906
			-
			5,86,12,661
	(ii) Undisputed Trade Receivables - considered doubtful	-	-
		-	-
		-	-
		-	-
		-	12,63,940
		-	12,63,940
	Grand Total	5,20,55,313	62,35,590
			1,84,535
			1,33,318
			3,906
			12,63,940
			5,98,76,601
9	<b>Cash and cash equivalents</b>		
	Cash on hand		3,035
	Balances with banks		6,105
	- In current accounts		9,23,980
	- In deposit accounts		1,78,532
			<b>11,05,547</b>
			<b>25,27,926</b>
10	<b>Loans</b>		
	Unsecured, considered good:-		
	Advances to employees		71,736
	Loans & Advances to related parties		81,458
			55,38,355
			<b>71,736</b>
			<b>56,19,813</b>
11	<b>Other current assets</b>		
	Advance to supplier		12,30,663
	Balances with government authorities		54,20,168
	Prepaid expenses		3,30,247
	Others		56,524
			<b>70,37,603</b>
			<b>75,33,908</b>

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
GÖNÜLLERİN İZMİR ŞİŞLİ MERKEZİ  
KARAYOLU: 783 041 1925

Notes	Particulars	As at 31 March 2023		As at 31 March 2022	
12	Share capital				
(a)	<b>Authorised</b>				
	200 equity shares of TRL 10,000		20,00,000		20,00,000
(b)	<b>Issued, Subscribed and fully paid up</b>				
	200 equity shares of TRL 10,000		20,00,000		20,00,000
	Share Capital Impact Ind AS29		10,10,244		-
			<b>30,10,244</b>		<b>20,00,000</b>
	Notes:				
	(i) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:				
	Particulars	As at 31 March 2023		As at 31 March 2022	
	Equity shares	Nos of Shares	Amount	Nos of Shares	Amount
	Shares outstanding at the beginning of the period	200	20,00,000	200	20,00,000
	Add: Shares issued during the period	-	-	-	-
	Shares outstanding at the end of the period	200	20,00,000	200	20,00,000
	(ii) Terms/rights attached to equity shares				
	In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts, if any. The distribution will be in proportion to the number of equity shares held by the shareholders.				
	(iii) Details of shares held by each shareholder holding more than 5% shares				
	Equity shares	As at 31 March 2023		As at 31 March 2022	
		Nos of Shares	% of Holding	Nos of Shares	% of Holding
	Alivira Animal Health Ltd, Ireland	280	100%	280	100%
12	<b>Other Equity</b>				
	<b>Retained Earnings</b>				
	Opening Balance			(10,43,579)	1,67,55,490
	Profit for the year			(1,89,78,684)	(1,70,90,196)
	Remeasurement Benefit			(41,58,997)	(7,08,874)
	Retained Earning Impact Ind AS29			5,27,22,178	-
	<b>Closing Balance</b>			<b>2,85,40,917</b>	<b>(10,43,579)</b>
	<b>ii) Other Reserves</b>				
	General reserve			1,84,43,499	1,22,53,825
	Corporate Emp. Expenses - Reserve			1,06,16,842	38,79,006
	Revaluation Reserve			78,00,274	51,82,487
	Capital reserve			74,261	49,339
				<b>3,69,34,875</b>	<b>2,13,64,656</b>
	<b>Other Equity (Total)</b>			<b>6,54,75,792</b>	<b>2,03,21,077</b>
13	<b>Non-current liabilities - Financial Liabilities</b>				
	From banks				
	Unsecured			-	1,82,160
				-	<b>1,82,160</b>
	<b>Particulars</b>	<b>Security, Terms of repayment &amp; Interest Rate</b>		<b>As at</b>	<b>As at</b>
	Türkiye Halk Bankası A.Ş.	Govt. Subsidized loan taken with 6 month moratorium period starting from April 2020. Loan is repayable in 30 installments with 1st installment due on Nov 2020. Repayable fully by April 2023 - Interest rate 7.5% per annum		<b>31 March 2023</b>	<b>31 March 2022</b>
				-	1,82,160
14	<b>Long term provisions</b>				
	Provision for employee benefits				
	(i) Provision for gratuity (net)			46,17,793	15,11,214
	(ii) Provision for compensated absences			4,66,477	2,45,301
				<b>50,84,270</b>	<b>17,56,515</b>

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çavuşoğlu Mah. Baskınlar Cad.  
No: 7/45 49710 NİĞDE  
Kartal IV.C. 733 041 1925

Provet Veteriner Ürünleri San. ve Tic. A.Ş.  
Notes to accounts for the year ended 31st March 2022  
All amounts are in Turkish Lira unless stated otherwise

Notes	Particulars	As at																																	
		31 March 2023	31 March 2022																																
<b>15</b>	<b>Current liabilities- Short term borrowings</b>																																		
	Secured Loan																																		
	From bank (Interest rate in the range of 14.75-15.5%)	42,25,795	85,00,000																																
	Unsecured Loan																																		
	From related party (Interest rate in the range of 3-4%)	11,45,25,245	8,26,18,717																																
	Current maturities of long-term debt from Halk Bank	1,82,160	20,99,647																																
	(Details of interest rates, Repayment terms & other terms are disclosed under note 13)																																		
		<b>11,89,33,199</b>	<b>9,32,18,364</b>																																
<b>16</b>	<b>Current - Trade payable</b>																																		
	Trade payable	6,97,65,422	6,21,99,929																																
		<b>6,97,65,422</b>	<b>6,21,99,929</b>																																
	<b>As at March'23</b>																																		
	<table border="1"> <thead> <tr> <th rowspan="2">Particulars</th> <th rowspan="2">Not Due</th> <th colspan="4">Outstanding for following periods from due date of payment #</th> <th rowspan="2">Total</th> </tr> <tr> <th>Less than 1 year</th> <th>1-2 years</th> <th>2-3 years</th> <th>More than 3 years</th> </tr> </thead> <tbody> <tr> <td>(i) Others</td> <td>2,24,04,410</td> <td>1,49,56,521</td> <td>5,49,939</td> <td>24,704</td> <td>3,15,60,253</td> <td>6,94,95,827</td> </tr> <tr> <td>(ii) Disputed dues - Others</td> <td>-</td> <td>-</td> <td>-</td> <td>8,509</td> <td>2,61,087</td> <td>2,69,596</td> </tr> <tr> <td><b>Grand Total</b></td> <td><b>2,24,04,410</b></td> <td><b>1,49,56,521</b></td> <td><b>5,49,939</b></td> <td><b>33,213</b></td> <td><b>3,18,21,340</b></td> <td><b>6,97,65,422</b></td> </tr> </tbody> </table>	Particulars	Not Due	Outstanding for following periods from due date of payment #				Total	Less than 1 year	1-2 years	2-3 years	More than 3 years	(i) Others	2,24,04,410	1,49,56,521	5,49,939	24,704	3,15,60,253	6,94,95,827	(ii) Disputed dues - Others	-	-	-	8,509	2,61,087	2,69,596	<b>Grand Total</b>	<b>2,24,04,410</b>	<b>1,49,56,521</b>	<b>5,49,939</b>	<b>33,213</b>	<b>3,18,21,340</b>	<b>6,97,65,422</b>		
Particulars	Not Due			Outstanding for following periods from due date of payment #					Total																										
		Less than 1 year	1-2 years	2-3 years	More than 3 years																														
(i) Others	2,24,04,410	1,49,56,521	5,49,939	24,704	3,15,60,253	6,94,95,827																													
(ii) Disputed dues - Others	-	-	-	8,509	2,61,087	2,69,596																													
<b>Grand Total</b>	<b>2,24,04,410</b>	<b>1,49,56,521</b>	<b>5,49,939</b>	<b>33,213</b>	<b>3,18,21,340</b>	<b>6,97,65,422</b>																													
	<b>As at March'22</b>																																		
	<table border="1"> <thead> <tr> <th rowspan="2">Particulars</th> <th rowspan="2">Not Due</th> <th colspan="4">Outstanding for following periods from due date of payment #</th> <th rowspan="2">Total</th> </tr> <tr> <th>Less than 1 year</th> <th>1-2 years</th> <th>2-3 years</th> <th>More than 3 years</th> </tr> </thead> <tbody> <tr> <td>(i) Others</td> <td>2,91,33,252</td> <td>80,79,351</td> <td>99,684</td> <td>-</td> <td>2,46,17,479</td> <td>6,19,29,766</td> </tr> <tr> <td>(ii) Disputed dues - Others</td> <td>-</td> <td>-</td> <td>8,509</td> <td>2,61,087</td> <td>-</td> <td>2,69,596</td> </tr> <tr> <td><b>Grand Total</b></td> <td><b>2,91,33,252</b></td> <td><b>80,79,351</b></td> <td><b>1,08,193</b></td> <td><b>2,61,087</b></td> <td><b>2,46,17,479</b></td> <td><b>6,21,99,362</b></td> </tr> </tbody> </table>	Particulars	Not Due	Outstanding for following periods from due date of payment #				Total	Less than 1 year	1-2 years	2-3 years	More than 3 years	(i) Others	2,91,33,252	80,79,351	99,684	-	2,46,17,479	6,19,29,766	(ii) Disputed dues - Others	-	-	8,509	2,61,087	-	2,69,596	<b>Grand Total</b>	<b>2,91,33,252</b>	<b>80,79,351</b>	<b>1,08,193</b>	<b>2,61,087</b>	<b>2,46,17,479</b>	<b>6,21,99,362</b>		
Particulars	Not Due			Outstanding for following periods from due date of payment #					Total																										
		Less than 1 year	1-2 years	2-3 years	More than 3 years																														
(i) Others	2,91,33,252	80,79,351	99,684	-	2,46,17,479	6,19,29,766																													
(ii) Disputed dues - Others	-	-	8,509	2,61,087	-	2,69,596																													
<b>Grand Total</b>	<b>2,91,33,252</b>	<b>80,79,351</b>	<b>1,08,193</b>	<b>2,61,087</b>	<b>2,46,17,479</b>	<b>6,21,99,362</b>																													
<b>17</b>	<b>Other Current liabilities</b>																																		
	Statutory remittances	9,82,528	7,44,333																																
	Payables on purchase of fixed assets	1,52,804	3,79,774																																
	Advances from customers	4,25,469	60,941																																
	Others	1,33,23,220	41,95,591																																
		<b>1,48,84,021</b>	<b>53,80,639</b>																																
<b>18</b>	<b>Short term provisions</b>																																		
	Provision for compensated absences	1,76,169	78,997																																
	Provision for gratuity	7,94,884	7,94,884																																
		<b>9,71,053</b>	<b>8,73,881</b>																																
<b>19</b>	<b>Deferred tax liabilities (net)</b>																																		
	On DTL On Ind AS 29	1,48,34,730	-																																
		<b>1,48,34,730</b>	<b>-</b>																																
<b>20</b>	<b>Current tax liabilities</b>																																		
	Provision for taxation (Net of Advance Tax : TRY NIL March 2022 : TRY 353,641)	-	79,882																																
		<b>-</b>	<b>79,882</b>																																

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çavuşoğlu Mah. Bakırköy/İstanbul  
No: 37500000000000000000  
K:1A/İ.Ö. 333 041 1925

SADECE BELİRLENEN AMAÇLI İMZALANMIŞTIR  
GÜNEY BAĞIMSIZ DENETİM VE SMMM A.Ş.

Provet Veteriner Ürünleri San. ve Tic. A.Ş.  
Notes to accounts for the year ended 31 March 2023  
All amounts are in Turkish Lira unless stated otherwise

Notes	Particulars	Year Ended 31 March 2023	Year Ended 31 March 2022
<b>21 Revenue from operations</b>			
	Gross Sales	27,83,60,702	12,12,28,547
	Less: Sales Return	4,47,323	6,76,301
	Less: Turnover Premium	84,04,846	51,27,859
	Net Sales	26,95,08,532	11,54,24,386
	Other operating revenues	4,42,55,249	1,65,58,150
		<b>31,37,63,781</b>	<b>13,19,82,537</b>
<b>22 Other Income</b>			
	Interest income	11,08,409	16,816
	Monetary Gain PL Ind AS 29	(1,59,31,739)	
	Net gain on sale of investments	21,745	1,19,129
	Net gain on sale of fixed asset	43,98,225	-
	Miscellaneous Income	14,86,179	10,15,550
		<b>(89,17,181)</b>	<b>11,51,496</b>
<b>23 Cost of materials consumed</b>			
	Opening stock	5,91,84,721	2,15,84,590
	Ind AS 29 Op. Stk Restatement	1,87,33,816	
	Add: Purchases	17,02,99,604	11,10,55,283
	Less: Closing stock	7,30,99,810	5,91,84,721
		<b>17,51,18,331</b>	<b>7,34,55,153</b>
<b>24 Changes in inventories of finished goods and work-in-progress &amp; intermediates</b>			
	Opening stock		
	Work-in-progress and intermediates	15,21,558	10,36,569
	Finished goods	1,25,64,243	66,29,200
		<b>1,40,85,802</b>	<b>76,65,769</b>
	<b>Ind AS 29 Op. Stk Restatement</b>	<b>19,39,644</b>	
	Closing stock		
	Work-in-progress and intermediates	26,24,636	15,21,558
	Finished goods	2,10,87,368	1,25,64,243
		<b>2,37,12,005</b>	<b>1,40,85,802</b>
	<b>Net (increase) / decrease</b>	<b>(76,86,559)</b>	<b>(64,20,033)</b>
<b>25 Employee benefits expense (refer note no 36)</b>			
	Salaries and wages	3,48,61,007	1,63,27,027
	Contribution to provident and other funds	55,38,274	35,88,261
	Corporate Emp. Expenses	9,07,086	11,08,287
	Staff welfare expenses	45,43,657	20,19,601
	Gratuity	1,98,588	4,71,696
		<b>4,60,48,612</b>	<b>2,35,14,872</b>
<b>26 Finance costs</b>			
	Interest expense	79,94,467	25,76,091
	Other borrowing costs	5,98,875	2,67,903
	Lease Interest costs	1,98,110	2,11,239
		<b>87,91,453</b>	<b>30,55,233</b>

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çayyolu Mah. İstanbul Anadolu  
Kadıköy / İstanbul / TÜRKİYE  
KARAVAN NO: 733 041 1925

SADECE BELİRLİ AMAÇLI İMZALANMIŞTIR  
GÜNEY BAĞIMSIZ DENETİM VE SMİM A.Ş.



Provet Veteriner Ürünleri San. ve Tic. A.Ş.  
Notes to accounts for the year ended 31 March 2023  
All amounts are in Turkish Lira unless stated otherwise

Notes	Particulars	Year Ended 31 March 2023	Year Ended 31 March 2022
27	<b>Depreciation and amortization expense</b>		
	Tangible assets	57,84,753	38,98,292
	Intangible assets	1,38,064	2,19,970
	Lease Assets	1,01,795	1,01,797
		<b>60,24,612</b>	<b>42,20,059</b>
28	<b>Other expenses</b>		
	Travel expenses	42,73,296	15,15,129
	Communication expenses	4,19,927	2,47,902
	Consumables	42,90,740	29,70,440
	Legal and Professional charges	45,33,454	23,43,930
	Freight and forwarding	45,42,034	17,78,495
	Power and fuel	97,12,935	34,72,837
	Rent	4,97,114	3,48,783
	Analytical charges	28,21,221	15,28,362
	Repairs to buildings	3,94,513	1,70,066
	Repairs to machinery	10,38,665	7,17,660
	Repairs to others	10,01,450	8,48,116
	Insurance	5,70,924	2,74,417
	Advertisement and selling expenses	36,43,090	42,90,187
	Rates and taxes	5,93,384	6,26,046
	Loss on sale of assets (net)	-	74,943
	Net loss on foreign currency transactions and translation	4,67,27,859	3,84,44,720
	Other expenses	55,47,158	33,74,424
		<b>9,06,07,764</b>	<b>6,30,26,457</b>
29	<b>Tax expense (refer note no 36)</b>		
	Deferred tax	8,97,791	(45,38,212)
	Def. Tax Expenses Ind AS29	40,23,281	
	Prior period tax		(60,89,302)
		<b>49,21,073</b>	<b>(1,06,27,514)</b>

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çavuşoğlu Mah. B. Kültür Yolu  
Nispetiye / Beşiktaş / İstanbul  
KURUMSAL MÜHÜR  
KURUMSAL MÜHÜR  
KURUMSAL MÜHÜR

SADECE BELİRLENEN AMAÇLI İMZALANMIŞTIR  
GÖNEY BAĞIMSIZ DENETİM VE SMMM A.Ş.

**Note 30 Details of leasing arrangements**

The Company's significant leasing arrangement is mainly in respect of office premises & Server; the aggregate lease rent payable on these leasing arrangements charged to Statement of Profit and Loss is TRY 343,194 (March'22 - TRY 279,294 ). Below is the movement of the asset

The following is the movement in lease liabilities:

Particulars	Year ended	Year ended
	31 March 2023	31 March 2022
Opening Balance	10,23,533	10,91,588
Accretion of interest	1,98,110	2,11,239
Payments	(2,79,294)	(2,79,294)
<b>Closing Balance</b>	<b>9,42,350</b>	<b>10,23,533</b>
Current	99,165	83,155
Non-current	8,43,185	9,40,378

The effective interest rate for lease liabilities is 24%, with maturity till Mar,2029

The following are the amounts recognised in profit or loss:

Particulars	Year ended	Year ended
	31 March 2023	31 March 2022
Depreciation expense of right-of-use assets	1,01,795	1,01,797
Interest expense on lease liabilities	1,98,110	2,11,239
Discontinue of lease asset	-	-
<b>Total amount recognised in profit or loss</b>	<b>2,99,905</b>	<b>3,13,036</b>

Maturity Analysis of Lease (Refer Note 34.4)

Impact on the statement of cash flows increase / (decrease)

Particulars	Year ended	Year ended
	31 March 2022	31 March 2021
Payment of principal portion of lease liabilities	(81,184)	(68,055)
Payment of interest portion of lease liabilities	(1,98,110)	(2,11,239)
<b>Net cash flows from financing activities</b>	<b>(2,79,294)</b>	<b>(2,79,294)</b>

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çavuşlu, Yeniköy, Beşiktaş/İstanbul Cad.  
No: 25 / Beşiktaş / İSTANBUL  
Kartal V.D.: 733 041 1925

Note 31 Earnings per share

Particulars	2023	2022
Net profit / (loss) for the period as per statement of profit and loss	(1,89,78,684)	(1,70,90,196)
Net profit / (loss) for the period attributable to the equity shareholders	(1,89,78,684)	(1,70,90,196)
Weighted average number of equity shares	200	200
Earnings / (Loss) per share - Basic	(94,893)	(85,451)
Earnings / (Loss) per share - Diluted	(94,893)	(85,451)

Note 32 Contingent liabilities and commitments

(i) Contingent liabilities

There is no contingent liabilities as on 31st March 2023 & 31st March 2022

(ii) Commitments

Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advances)

	31-Mar-23	31-Mar-22
Tangible Fixed assets	Nil	Nil

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çavuşoğlu Meh. Baskın Cad.  
Nispetiye / BEŞİKÖZ / İSTANBUL  
KURUMSAL NO: 2733 041 1925

### 33 Financial instruments

The carrying value / fair value of financial instruments by categories are as follows:

Financial assets	Carrying value and fair value	
	31 March 2023	31 March 2022
<b>Measured at amortised cost</b>		
Loans	71,736	56,19,813
Trade receivables	10,44,72,904	5,86,12,727
Cash and cash equivalents	11,05,547	25,27,926
Other financial assets		
Other investments	1,84,88,435	1,62,20,719
<b>Total</b>	<b>12,41,38,622</b>	<b>8,29,81,184</b>
<b>Financial liabilities</b>		
<b>Measured at amortised cost</b>		
Borrowings (including current maturity of long-term borrowings)	11,89,33,199	9,34,00,524
Trade payables	6,97,65,422	6,21,99,929
Other financial liabilities	9,42,350	10,23,533
<b>Total</b>	<b>18,96,40,971</b>	<b>15,66,23,986</b>

### 33.2 Financial risk management objective and policies

The Company's principal financial liabilities comprise loans and borrowings, trade payables and other payables. The main purpose of these financial liabilities is to finance the company's operations. The company's principal financial assets include investments, loans, trade and other receivables, and cash and deposits that derive directly from its operations.

The Company is exposed to the following risks from its use of financial instruments:

- Credit risk
- Liquidity risk
- Market risk

This note presents information about the Company's exposure to each of the above risks, the company's objectives, policies and processes for measuring and managing risk, and the company's management of capital. Further quantitative disclosures are included throughout these financial statements.

#### Risk management framework

The company's activities makes it susceptible to various risks. The company has taken adequate measures to address such concerns by developing adequate systems and practices. The company's overall risk management program focuses on the unpredictability of markets and seeks to manage the impact of these risks on the company's financial performance.

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çavuşodlu Mah. Etiler Köyü  
No: 33 KAT: 7 İSTANBUL  
KataV.C.: 733 041 1026

### 34.3 Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations resulting in a financial loss to the Company. Credit risk arises principally from trade receivables. Credit risk arises from cash held with banks and financial institutions, as well as credit exposure to customers, including outstanding accounts receivables. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses in financial assets. The Company monitors the credit quality of the counterparties, taking into account their financial position, past experience and other factors.

The credit risk on liquid funds and derivative financial instruments is limited because the counterparties are banks with high credit-ratings assigned by credit-rating agencies.

The Company's trade and other receivables are actively monitored to review creditworthiness of the customers to whom credit terms are granted and also avoid significant concentrations of credit risks.

Given below is ageing of trade receivable spread by period of six months:

	31 March 2023	31 March 2022
Outstanding for more than 6 months	16,87,823	3,21,759
Others	10,27,85,082	5,82,90,968
<b>Total</b>	<b>10,44,72,904</b>	<b>5,86,12,727</b>

#### Information about major Customer

One customer has total exposure in sales TRY 2,85,83,287 (9 % of total sales) in current year and TRY 1,80,92,262 (16 % of total sales) in FY 22. The receivables from this customer is TRY 1,91,90,813 (18% of total receivable) in current year and TRY 1,44,09,735 (25% of total receivable) in FY 22. Apart from the aforesaid customers, the Company does not have a significant credit risk exposure to any other external counterparty.

### 33.4 Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company reputation.

The Company has an appropriate liquidity risk management framework for the management of short, medium and long term funding and liquidity management requirements. The Company manages liquidity risk by maintaining adequate cash reserves, banking facilities and reserve borrowing facilities by continuously monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities.

The table below provides details regarding the contractual maturities of significant financial liabilities as at 31 March 2023 and 31 March 2022:

Particulars	As at 31 March 2023			
	Less than 1 year	1-2 years	2 years and above	Total
Borrowings (including current maturity of long-term borrowings)	11,89,33,199			11,89,33,199
Trade payables	3,73,60,931	5,49,939	3,18,54,553	6,97,65,422
Lease liability	83,155	1,01,609	7,57,586	9,42,350

Particulars	As at 31 March 2022			
	Less than 1 year	1-2 years	2 years and above	Total
Borrowings (including current maturity of long-term borrowings)	9,11,18,717	20,99,647	1,82,160	9,34,00,524
Trade payables	6,21,99,929			6,21,99,929
Lease liability	83,155	1,01,609	8,38,770	10,23,534

### 33.5 Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return.

The Company is exposed to interest rate risk arises mainly from debt. The Company is exposed to interest rate risk because the fair value of fixed rate borrowings and the cash flows associated with floating rate borrowings will fluctuate with changes in interest rates.

The Company is also exposed to foreign currency risk on certain transactions that are denominated in a currency other than the Company's functional currency; hence exposures to exchange rate fluctuations arise. The risk is that the functional currency value of cash flows will vary as a result of movements in exchange rates.

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Cavuşlu Mah. Kavutlu Cad.  
No: 28 Kartal / İSTANBUL  
Kartal V.D.: 733 041 1926

SADECE BELİRLEMENİMLİ İMZALANMIŞTIR  
GÜNEY BAĞIMSIZ DENETİM VE SMMM A.Ş.

**Foreign currency Risk:**

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Company's exposure to the risk of changes in foreign exchange rates relates primarily to the Company's financing activities & operating activity. The Company manages its foreign currency risk of operating activity & finance activities (excluding group exposure) by having limited exposure.

**a) Foreign currency risk exposure from financial instruments are given below**

Foreign currency	31 March 2023		31 March 2022	
	Receivables / (payables)	Receivables / (payables) in foreign currency	Receivables / (payables)	Receivables / (payables) in foreign currency
EURO	(2,47,07,394)	(11,87,733)	(2,01,54,649)	(12,35,830)
USD	(11,57,09,688)	(60,43,544)	(9,08,39,941)	(62,02,457)
<b>Net exposure</b>	<b>(14,04,17,081)</b>		<b>(11,09,94,590)</b>	

**b) Foreign currency sensitivity analysis**

The Company is mainly exposed to currency fluctuation of USD and Euro.

The following table details the Company's sensitivity to a 10% increase and decrease in the TRY against the relevant foreign currencies. The sensitivity analysis includes only outstanding foreign currency denominated monetary items and adjusts their translation at the period end for 10% change in foreign currency rates. A positive numbers below indicates an increase in profit or equity where the TRY strengthens 10% against the relevant currency. For a 10% weakening of the TRY against the relevant currency, there would be a comparable impact on the profit or equity, and the balance below would be negative.

	Impact on profit or loss and total equity	
	31 March 2023	31 March 2022
<b>10% decrease in foreign currency</b>		
Currency of Europe (Euro)	24,70,739	20,15,465
Currency of U.S.A (USD)	1,15,70,969	90,83,994
<b>10% increase in foreign currency</b>		
Currency of Europe (Euro)	(24,70,739)	(20,15,465)
Currency of U.S.A (USD)	(1,15,70,969)	(90,83,994)

In management's opinion, the sensitivity analysis is unrepresentative of the inherent foreign exchange risk because the exposure at the end of the reporting period does not reflect the exposure during the year.

**c) Interest rate risk exposure**

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's long-term debt obligations with floating interest rates.

At the reporting date the interest rate profile of the Company's interest-bearing financial instruments are as follows:

	31 March 2023	31 March 2022
Financial liabilities		
-Borrowings from bank	42,25,795	86,82,160
-Borrowings from related party	11,45,25,245	8,26,18,717
	<b>11,87,51,039</b>	<b>9,13,00,877</b>

**Fair value sensitivity analysis for fixed-rate instruments**

The Company does not account for any fixed rate financial assets and liabilities at fair value through profit or loss. Therefore a change in interest rates at the reporting date would not affect profit or loss.

**33.6 Capital management**

For the purpose of Company's capital management, capital includes issued equity capital and all other

	31 March 2023	31 March 2022
Debt (i)	11,89,33,199	9,34,00,524
Cash and bank balances (ii)	11,05,547	25,27,926
Current investment (iii)	-	-
<b>Net debt [ (i) - { (ii)+(iii)+(iv) } ]</b>	<b>11,78,27,652</b>	<b>9,08,72,598</b>
<b>Equity attributable to owners of the Company</b>	<b>6,84,86,036</b>	<b>2,23,21,077</b>
<b>Gearing ratio : Net debt / Equity.</b>	<b>172.05%</b>	<b>407.12%</b>

(i) Debt is defined as long-term (including current maturity on long-term borrowings) and short-term borrowings

Provet Veteriner Ürünleri San. ve Tic. A.Ş.  
Notes to accounts for the year ended 31 March 2023  
All amounts are in Turkish Lira unless stated otherwise

**Note 34 - Segment Information**

Segments have been identified taking into account the nature of services, the differing risks and returns, the organisational structure and the internal reporting system

**Primary segment: Business segment**

The Company is mainly engaged in the business of manufacturing and marketing of Vet Pharmaceutical products. Considering the nature of business and financial reporting of the Company, the Company has only one business segment viz; Vet formulation as primary reportable segment.

**Secondary Segment Information (Geographical Segment)**

Particulars	Year Ended 31 March 2023	Year Ended 31 March 2022
<b>Revenue from operation</b>		
Europe	89,90,862	12,31,12,826
Asia	28,09,65,354	15,76,073
Rest of the World	2,38,07,565	72,93,637
<b>Total</b>	<b>31,37,63,781</b>	<b>13,19,82,537</b>
<b>Segment Assets</b>		
Europe	25,28,579	2,13,728
Asia	25,80,27,683	15,98,15,558
Rest of the World	1,47,84,649	51,66,162
<b>Total</b>	<b>27,53,40,911</b>	<b>16,51,95,447</b>
<b>Unallocable Asset</b>	<b>1,85,60,171</b>	<b>2,18,40,532</b>
<b>Total Assets</b>	<b>29,39,01,082</b>	<b>18,70,35,979</b>
<b>Cost incurred during the year to acquire segment assets (tangible and intangible fixed assets)</b>		
Asia	38,07,751	37,08,448
<b>Total</b>	<b>38,07,751</b>	<b>37,08,448</b>

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çavuşoğlu Mah. Beşiktaş Cad.  
No: 11 Kat: 7 İSTANBUL  
Kartal/İl. 733 041 1925

SADECE BELİRLENEN MAÇLI İMZALANMIŞTIR  
GÜNEY BAĞIMSIZ DENETİM VE SMMM A.Ş.

35 Employee benefit plans

(i) **Defined contribution plans:**

The Company makes Social Security scheme contributions which are defined contribution plans, for all employees. Under the scheme, the company is required to contribute a specified percentage payroll costs to fund the benefits. The Company has recognised TL 55,38,274 (31 March 2021 : TL 35,88,261) for social security scheme contributions.

(ii) **Defined benefit plans:**

The Company has termination benefits for its employees. Termination benefits are payable to all eligible employees of the Company on superannuation, death and resignation. The following table summarises the components of net employee benefit expenses recognised in the statement of profit and loss and the funded status and amounts recognised in the balance sheet for the plan.

	<u>31 March 2023</u>	<u>31 March 2022</u>
	<u>Termination benefits</u>	<u>Termination benefits</u>
<b>Expense/ (income) recognised in the statement of profit and loss:</b>		
Current service cost	8,59,978	4,71,699
Net interest cost	4,57,315	1,82,283
Expected return on plan assets	-	-
<b>Component of defined benefit costs recognised in the statement of profit and loss</b>	<b>13,17,293</b>	<b>6,53,982</b>
<b>Expense / (income) recognised in other comprehensive income:</b>		
Return on plan assets (excluding amounts included in net interest cost)	-	-
Actuarial (gains) / losses arising from changes in demographic assumptions	-1,26,546	5,64,593
Actuarial (gains) / losses arising from changes in financial assumptions	16,22,663	1,82,882
Actuarial (gains) / losses arising from changes in experience adjustments	26,62,880	(38,601)
<b>Component of defined benefit costs recognised in the other comprehensive income</b>	<b>41,58,997</b>	<b>7,08,874</b>
<b>Total</b>	<b>54,76,290</b>	<b>13,62,856</b>

The current service cost is included in 'Employee benefit expenses' and net interest cost is included in the 'Finance costs' line item in the statement of profit and loss.

The remeasurement of the net defined benefit liability is included in other comprehensive income.

**Net defined benefit obligation as reflected in balance sheet:**

	<u>31 March 2023</u>	<u>31 March 2023</u>
	<u>Termination benefits</u>	<u>Termination benefits</u>
Present value of defined benefit obligation (DBO)	54,12,678	23,06,101
Fair value of plan assets	-	-
Funded status [surplus / (deficit)]	(54,12,678)	(23,06,101)
<b>Net liability recognised in balance sheet</b>	<b>54,12,678</b>	<b>23,06,101</b>

**A. Movements in the present value of the defined benefit obligation are as follows:**

	<u>31 March 2023</u>	<u>31 March 2022</u>
	<u>Termination benefits</u>	<u>Termination benefits</u>
Opening balance	23,06,101	11,41,456
Current service cost	8,59,978	4,71,699
Interest cost	4,57,315	1,82,283
Benefits paid	(23,69,713)	(1,98,211)
<b>Re-measurement loss/ (gain):</b>		
<b>Actuarial loss/ (gain) arising from:</b>		
Actuarial (Gain) / Loss - Demographic Assumptions	(1,26,546)	5,64,593
Actuarial (gains) / losses arising from changes in financial assumptions	16,22,663	1,82,882
Actuarial (gains) / losses arising from changes in experience adjustments	26,62,880	(38,601)
Exchange gain or loss	-	-
<b>Closing defined benefit obligation</b>	<b>54,12,678</b>	<b>23,06,101</b>

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çayırcağılı Mah. Başkent Caddesi  
Nispetiye / Beşiktaş / İstanbul  
Kartal IV. S. 733 041 1925

SADECE BELİRLEME İMZALANMIŞTIR  
GÜNEY BAĞIMSIZ DENETİM VE SMİM A.Ş.



## Actuarial assumptions

The principal assumptions used for the purpose of actuarial valuations are shown in the table below. The assumptions as at the balance sheet date are used to determine the present value of defined benefit obligation at that date.

	<u>31 March 2023</u>	<u>31 March 2022</u>
	<u>Termination</u>	<u>Termination</u>
	<u>benefits</u>	<u>benefits</u>
<b>Financial assumption:</b>		
Discount rate	10.90%	23.96%
Salary escalation rate	44% first year,10% thereafter	19.62%
<b>Demographic assumption:</b>		
Withdrawal rate	20%	19%
Mortality rate	IALM (2012- 14) Ultimate	IALM (2012-14) Ultimate
Retirement age	58-60	58-60

As per para 83 of Ind As 19-Employee benefits, the rate used to discount post-employment benefit obligation (both funded and unfunded) shall be determined by reference to market yields at the end of each reporting period on government bonds.

	<u>31 March 2023</u>	<u>31 March 2022</u>
	<u>Termination</u>	<u>Termination</u>
	<u>benefits</u>	<u>benefits</u>
<b>Expected future cash flows</b>		
Within 1 year	17,76,280	7,94,884
2-5 years	34,64,448	22,57,585
6-10 years	18,48,703	12,47,951

## Sensitivity Analysis

The sensitivity analyses below have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period. The sensitivity analyses are based on a change in a significant assumption, keeping all other assumptions constant. The sensitivity analyses may not be representative of an actual change in the defined benefit obligation as it is unlikely that changes in assumptions would occur in isolation from one another.

	<u>Impact on the defined benefit obligation</u>	
	<u>Termination benefits</u>	
	<u>100 bps increase</u>	<u>100 bps decrease</u>
<b>31 March 2023</b>		
Discounting rate	(2.67)	2.85
Salary escalation rate	0.64	(0.73)
<b>31 March 2022</b>		
Discounting rate	(2.05)	(2.14)
Salary escalation rate	0.37	(0.39)

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Çavuşbaşı Mh. Baskınlar Cd. No: 10  
Kartal/İSTANBUL  
Kartal V.İ. 733 041 1925

SADECE BELİRLEME AMAÇLI İMZALANMIŞTIR  
GÜNEY BAĞIMSIZ DENETİM VE SMMM A.Ş.

36 Reconciliations of tax expenses and details of deferred tax balances

A) Income tax expense recognised in the statement of profit and loss

	Year ended 31 March 2023	Year ended 31 March 2022
<b>i) Income tax expense recognised in the statement of profit and loss</b>		
Current tax	-	-
<b>Total (I)</b>	-	-
<b>Deferred tax charge</b>		
Origination and reversal of temporary differences	49,21,073	(45,38,212)
<b>Total (II)</b>	49,21,073	(45,38,212)
<b>Provision for tax of earlier years Provided (III)</b>	-	-60,89,302
<b>Total (IV = I+II+III)</b>	49,21,073	(1,06,27,514)

The current tax is calculated using tax rates that have been enacted or substantively enacted by the end of each reporting period. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the end of each reporting period.

B) Reconciliation of effective tax rate

The reconciliation between the statutory income tax rate applicable to the Company and the effective income tax rate of the

	31 March 2023	31 March 2022
<b>Profit before tax</b>	<b>(1,40,57,612)</b>	<b>(2,77,17,710)</b>
Statutory income tax rate	25.00%	20.00%
<b>Tax as per applicable tax rate</b>	-	-55,43,542
<b>Differences due to:</b>		
- Effect of deferred tax on brought forward business losses	12,07,779	
- Effect of change in tax rate		1,69,594
- Provision for tax of earlier years	(60,89,302)	20,66,472
- Others	(7,44,663)	(5,03,620)
<b>Income tax expenses charged to the statement of profit and loss</b>	<b>(56,26,187)</b>	<b>(38,11,095)</b>
Effective tax rate	40.0%	13.7%

C) Movement in deferred tax assets and liabilities

31 March 2023			
	As at 01 April 2022	Credit / (charge) in the statement of profit and loss	As at 31 March 2023
- Temporary differences on account of depreciation	(6,65,463)	1,38,403	(5,27,060)
- ESOP	2,77,072	2,26,772	5,03,843
- Right-of-use assets (^)	88,489	5,153	93,642
- Other	8,50,406	(60,340)	7,90,066
- Ind AS 29	-	(1,48,34,730)	(1,48,34,730)
<b>Tax assets / (liabilities)</b>	<b>5,50,504</b>	<b>(1,45,24,742)</b>	<b>(1,39,74,238)</b>
- Unabsorbed depreciation and carried forward of losses	37,93,549	(12,07,779)	25,85,770
<b>Net tax assets / (liabilities)</b>	<b>43,44,053</b>	<b>(1,57,32,521)</b>	<b>-1,13,88,468</b>
- MAT credit entitlement	-	-	-
<b>Total</b>	<b>43,44,053</b>	<b>(1,57,32,521)</b>	<b>-1,13,88,468</b>

31 March 2022			
	As at 01 April 2021	Credit / (charge) in the statement of profit and loss	As at 31 March 2022
- Temporary differences on account of depreciation	(7,57,924)	92,461	(6,65,463)
- ESOP	-	2,77,072	2,77,072
- Right-of-use assets (^)	64,042	24,446	88,489
- Other	4,99,723	3,50,684	8,50,406
<b>Tax assets / (liabilities)</b>	<b>(1,94,159)</b>	<b>7,44,663</b>	<b>5,50,504</b>
- Unabsorbed depreciation and carried forward of losses	-	37,93,549	37,93,549
<b>Net tax assets / (liabilities)</b>	<b>(1,94,159)</b>	<b>45,38,212</b>	<b>43,44,053</b>
- MAT credit entitlement	-	-	-
<b>Total</b>	<b>(1,94,159)</b>	<b>45,38,212</b>	<b>43,44,053</b>

(^) Opening balances is on account of transition impact of Ind AS 116.

Note 37 - Related Party Disclosures

- i) **Holding company:**  
Alivira Animal Health Limited, Ireland  
Alivira Animal Health Limited, India (Holding company of Alivira Animal Health Limited, Ireland)  
Sequent Scientific Limited, India (Ultimate Holding Company)
- ii) **Wholly owned Subsidiary :**  
Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.
- iii) **Key Management Personnel**  
Murat Mentès (Date of appointment – November 16, 2020)  
Alexis Goux (Date of appointment - March 22, 2022)
- iv) **Fellow Subsidiaries**  
Laboratorios Karizoo SA, Spain  
Bremer Pharma GmbH, Germany

A. Transaction during the year	Year ended 31	Year ended 31
Nature of Transactions	March 2023	March 2022
<b>(i) Purchase of materials</b>		
Alivira Animal Health Ltd, India	2,45,858	93,699
Laboratorios Karizoo SA, Spain	1,07,51,595	-
Bremer Pharma GmbH, Germany	1,89,403	-
Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.	4,53,70,991	2,83,23,648
<b>(ii) Sale of materials</b>		
Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.	6,11,66,119	3,83,93,134
<b>(iii) Interest on Loan</b>		
Alivira Animal Health Ltd, Ireland	36,55,347	21,06,776
<b>(iv) Income from Car rent cross charge</b>		
Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.	27,00,000	15,00,000
<b>(v) Income from Conversion charges cross charge</b>		
Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.	3,98,00,000	1,42,50,000
<b>(vi) Rent charges for office &amp; warehouse</b>		
Dr. Huseyin Aydın	3,00,000	3,43,333
<b>(vii) Income from Logistic Service</b>		
Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.	5,53,602	3,73,760
<b>(viii) Income from fuel expense reimbursement</b>		
Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.	4,87,592	1,69,563
<b>(ix) Legal &amp; professional Expenses</b>		
Alivira Animal Health Limited, Ireland	2,49,292	-
Laboratorios Karizoo SA, Spain	16,82,723	4,60,218
<b>(x) Other Expenses</b>		
Bremer Pharma GmbH, Germany	98,492	-
<b>B. Balance as at balance sheet date:</b>		
<b>(i) Borrowing</b>		
Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.	26,14,259	-
Alivira Animal Health Ltd, Ireland	11,19,07,391	8,26,18,717
<b>(ii) Advances given</b>		
Topkim-Topkapi İlaç Premiks San. Ve Tic. A.Ş.	-	55,38,355
<b>(iii) Receivable balance</b>		
Bremer Pharma GmbH, Germany	-	2,13,728
<b>(iv) Creditors balance</b>		
Laboratorios Karizoo SA, Spain	66,80,528	5,12,502
Bremer Pharma GmbH, Germany	41,518	-
Alivira Animal Health Ltd, India	-	34,418
Alivira Animal Health Ltd, Ireland	3,18,09,545	2,46,17,087

The accompanying notes are an integral part of the financial statements.

As per our report of event date  
EY Turkey  
Auditors

Place : İstanbul  
Date : 20 May 2023

For and on Behalf of the Board of Directors

Murat Mentès  
Director  
Thane, 20 May 2023

PROVET VETERİNER ÜRÜNLERİ  
SAN. VE TİC. A.Ş.  
Kartal, İstanbul  
733 041 1925

SADECE BELİRLEME AMAÇLI İMZALANMIŞTIR  
GÜNEY BAĞIMSIZ GEMERİM VE SMMM A.Ş.